Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21
News

Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21

The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.

  • By IPP Bureau | February 01, 2021

Dr. Reddy's Laboratories has reported total income of Rs.4929.6 crores during the period ended December 31, 2020 as compared to Rs.4896.7 crores during the period ended September 30, 2020.

 

The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net profit of Rs.762.3 crores for the period ended September 30, 2020.

 

The company has reported EPS of Rs.1.19 for the period ended December 31, 2020 as compared to Rs.45.83 for the period ended September 30, 2020.

 

Dr. Reddy's Laboratories has reported total income of Rs.4929.6 crores during the period ended December 31, 2020 as compared to Rs.4383.8 crores during the period ended December 31, 2019.

 

The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.

 

The company has reported EPS of Rs.1.19 for the period ended December 31, 2020 as compared to Rs.(34.37) for the period ended December 31, 2019.

 

Dr. Reddy's Laboratories has reported total income of Rs.14243.8 crores during the 9 months period ended December 31, 2020 as compared to Rs.13028.2 crores during the 9 months period ended December 31, 2019.

 

The company has posted net profit / (loss) of Rs.1361.4 crores for the 9 months period ended December 31, 2020 as against net profit / (loss) of Rs.1185.6 crores for the 9 months period ended December 31, 2019.

 

The company has reported EPS of Rs.81.85 for the 9 months period ended December 31, 2020 as compared to Rs.71.40 for the 9 months period ended December 31, 2019.

 

The effective tax rate is ~93.0% for the quarter, impacted primarily due to non-recognition of deferred tax asset on impairment.

Upcoming E-conference

Other Related stories

Startup

Digitization